8-Bromoadenine - ≥97% , CAS No.6974-78-3

CAS: 6974-78-3 Cat. No.: B353415 Summenformel: C5H4BrN5 Molekulargewicht: 214.03 EG-Nummer: 230-225-1
Zu bestellen verfügbar
QUALITÄT & REINHEIT ≥97%
Synonyms
8-Bromo adenine|8-bromadenin|9H-Purin-6-amine,8-bromo-|8-Bromo-1H-adenine|1H-Purin-6-amine, 8-bromo-|8-bromo-7H-purin-6-amine|6-Amino-8-bromopurine|8-Bromo-9H-purin-6-ylamine0.9M HCl|8-Bromo-9H-purin-6-amine|8-Br-adenine|8-bromopurine-6-ylamine|Brl-42359|2-[[3-(2-Quinolinylmethoxy)phenyl]a|8-Bromo-9H-purin-6-amine #|8-Bromoadenine|Taurocholic sodium
Storage
Store at 2-8°C
Shipped In
Wet ice
★
Größe
Deutschland (EU)
USA*
Preis
Menge
100mg
B353415-100mg
—
5 Auf Lager

25,08€

38,09€
Speichern 13,02 € (34.17%)
250mg
B353415-250mg
—
3 Auf Lager

32,02€

48,51€
Speichern 16,49 € (33.99%)
1g
B353415-1g
—
2 Auf Lager

117,06€

176,06€
Speichern 59,01 € (33.51%)
Enter a quantity for the sizes you want to add.

Spezifikationen

Synonyme
8-Bromo adenine | 8-bromadenin | 9H-Purin-6-amine,8-bromo- | 8-Bromo-1H-adenine | 1H-Purin-6-amine, 8-bromo- | 8-bromo-7H-purin-6-amine | 6-Amino-8-bromopurine | 8-Bromo-9H-purin-6-ylamine0.9M HCl | 8-Bromo-9H-purin-6-amine | 8-Br-adenine | 8-bromopurine-6-ylamine | Brl-42359 | 2-[[3-(2-Quinolinylmethoxy)phenyl]a | 8-Bromo-9H-purin-6-amin Show more
Spezifikationen & Reinheit
≥97%
Storage
Store at 2-8°C
Verschickt in
Wet ice
Dieses Produkt erfordert Kühlkettenversand. Grundversand und andere Economy-Optionen sind nicht verfügbar.
Reinheit
≥97%
Namen und Kennungen
Pubchem Sid
Pubchem Sid Url
https://pubchem.ncbi.nlm.nih.gov/substance/488185971
SMILES
C1=NC(=C2C(=N1)N=C(N2)Br)N
IUPAC Name
8-bromo-7H-purin-6-amine
InChIKey
FVXHPCVBOXMRJP-UHFFFAOYSA-N
InChI
1S/C5H4BrN5/c6-5-10-2-3(7)8-1-9-4(2)11-5/h1H,(H3,7,8,9,10,11)
Isomere SMILES
C1=NC(=C2C(=N1)N=C(N2)Br)N
Molekulargewicht
214.03
Reaxy-Rn
1107211
Reaxys-RN_link_address
https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=1107211&ln=

Erweiterte Daten

Taxonomic Classification

Taxonomy Tree

KingdomOrganic compounds
SuperclassOrganoheterocyclic compounds
KlasseImidazopyrimidines
SubclassPurines and purine derivatives
Intermediate Tree Nodes Not available
Direct Parent6-aminopurines
Alternative Parents Aminopyrimidines and derivatives  Imidolactams  Aryl bromides  Imidazoles  Heteroaromatic compounds  Azacyclic compounds  Primary amines  Organopnictogen compounds  Organobromides  Hydrocarbon derivatives  
Molecular FrameworkAromatic heteropolycyclic compounds
Substituents 6-aminopurine - Aminopyrimidine - Aryl bromide - Aryl halide - Pyrimidine - Imidolactam - Imidazole - Azole - Heteroaromatic compound - Azacycle - Organopnictogen compound - Primary amine - Organonitrogen compound - Organobromide - Organohalogen compound - Amine - Organic nitrogen compound - Hydrocarbon derivative - Aromatic heteropolycyclic compound
BeschreibungThis compound belongs to the class of organic compounds known as 6-aminopurines. These are purines that carry an amino group at position 6. Purine is a bicyclic aromatic compound made up of a pyrimidine ring fused to an imidazole ring.
External Descriptors Not available
3D-Struktur
Interaktives chemisches Strukturmodell





Zugehörige Ziele (menschlich)
ADORA1 Tclin Adenosine A1 receptor (17603 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADORA2A Tclin Adenosine A2a receptor (16305 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADORA2B Tclin Adenosine A2b receptor (7672 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Wirkungsmechanismen
Zertifikate (CoA, COO, BSE/TSE und Analyse-Diagramm)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Find and download the COA for your product by matching the lot number on the packaging.

6 results found

Lot NumberCertificate TypeDatumArtikel
D2321740D2321740Certificate of AnalysisMar 20, 2023 B353415
D2321741D2321741Certificate of AnalysisMar 20, 2023 B353415
D2321742D2321742Certificate of AnalysisMar 20, 2023 B353415
D2321743D2321743Certificate of AnalysisMar 20, 2023 B353415
D2321752D2321752Certificate of AnalysisMar 20, 2023 B353415
D2321753D2321753Certificate of AnalysisMar 20, 2023 B353415
Chemische und physikalische Eigenschaften
LöslichkeitSoluble in 0.1N NaOH. Hardly soluble in hot water, DMSO. Insoluble in alcohol, ether, chloroform.
Siedepunkt (°C)~497.5° C at 760 mmHg (Predicted)
Schmelzpunkt (°C)>250° C
Molekulargewicht214.020 g/mol
XLogP30.800
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count4
Rotatable Bond Count0
Exact Mass212.965 Da
Monoisotopic Mass212.965 Da
Topological Polar Surface Area80.500 Ų
Heavy Atom Count11
Formal Charge0
Complexity154.000
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
The total count of all stereochemical bonds0
Covalently-Bonded Unit Count1
Lösungsrechner
Bewertungen

Kundenbewertungen

Application Protocols

No standardized biological assay protocols are claimed for this item. Usage is application-dependent (synthetic chemistry, nucleoside assembly, or in vitro biophysical assays).

General preparation examples (research use; adapt to your system)

  • Stock solution for screening: Dissolve to 100 mM in anhydrous DMSO; vortex and sonicate gently if needed. Filter (0.22 µm PTFE) for particulate removal. Store aliquots at 2–8 °C or frozen; minimize freeze–thaw.
  • Aqueous working solutions: Dilute DMSO stock into buffer (e.g., 10 mM Tris, pH 8.0) to a final DMSO content ≤1–2% v/v to maintain solubility. Prepare fresh.
  • Cross-coupling setup: Charge flame-dried vial with 8-bromoadenine, aryl boronic acid (1.2–1.5 equiv), base (3 equiv), Pd catalyst (1–2 mol%), and DMF/H2O (10:1). Heat 80–90 °C under N2 until TLC/LC-MS indicates completion; work up by dilution, filtration through celite, and crystallization or chromatography.

Assay notes

  • Verify compound integrity by LC-MS/NMR prior to sensitive measurements.
  • Avoid prolonged exposure to strong base or high temperature in aqueous media to limit degradation.

For detailed, validated protocols, consult primary literature aligned with your transformation or assay.

Biological Roles

Context: This section provides general, literature-based background on adenine analogs in biochemical research; it does not imply any clinical or diagnostic use.

  • Structural analog of adenine

    • 8-Bromination perturbs the electronic distribution of the purine ring and can influence base stacking and hydrogen-bonding patterns in nucleic acid contexts (in vitro models).
    • Such modifications are useful for probing enzyme–substrate recognition, nucleotide binding pockets, and nucleic acid conformational preferences.
  • Enzymology and binding studies (in vitro)

    • 8-substituted adenines and their nucleosides/nucleotides are commonly employed to map active sites of adenine-binding enzymes (e.g., kinases, polymerases, deaminases) by modulating steric/electronic features at the 8-position.
    • Photophysical and spectroscopic probes: Changes in UV absorbance and fluorescence quenching can be leveraged to track interactions in nucleic acid–protein assemblies.
  • Nucleoside/nucleotide derivatization

    • 8-bromoadenine serves as a precursor to 8-substituted adenosines/AMPs used in structural biology (e.g., crystallography co-crystals) and biophysical assays (e.g., melting curves), where C8 modification provides controlled perturbations.
  • Important caveats

    • Biological activity depends strongly on the exact derivative (nucleoside/nucleotide, protecting groups, substituent), concentration, and system studied.
    • No claims are made regarding therapeutic or diagnostic performance. Use strictly for research in appropriate containment following institutional guidelines.
Buffer Applications

This compound is not a buffering agent and is not typically used to prepare buffer systems.

  • Practical notes for solution prep in buffered media (research use)
    • Prepare a concentrated stock in DMSO (e.g., 10–100 mM, as solubility permits) and dilute into the working buffer with vigorous mixing.
    • Alternatively, dissolve directly in mildly basic buffers (pH 8–9; e.g., Tris, borate, carbonate) with gentle warming to aid solubility.
    • Filter-sterilize solutions if required for sensitive assays; avoid prolonged storage in aqueous solution to minimize hydrolysis/degradation.

For pH-stable systems, select buffers appropriate to your downstream assay; the compound itself does not impart buffering capacity.

Green Alternatives

Greener practice focuses on solvent and catalyst choices, since the substrate itself (a brominated heteroaromatic) is fixed.

  • Solvent substitutions (literature-guided)

    • Replace DMF/DMAc/NMP with more benign media where feasible: 2-methyltetrahydrofuran (2-MeTHF), cyclopentyl methyl ether (CPME), propylene carbonate (PC), or water/ethanol systems with phase transfer.
    • For Suzuki couplings, consider ethanol/water or 2-MeTHF with aqueous base; many boronic acids perform well in mixed green solvents.
    • For SNAr, sulfolane or PC can sometimes substitute for DMSO/DMF while maintaining polarity.
  • Catalysis and conditions

    • Employ ligand-efficient Pd systems at low loading (≤1 mol%) or explore Ni-catalyzed couplings with air-stable precatalysts.
    • Microwave or flow chemistry can shorten reaction times, lowering energy input.
  • Workup and purification

    • Favor aqueous crystallization or minimal solvent trituration over silica chromatography when possible.
    • Use greener eluents (ethyl acetate/hexanes replaced by EtOAc/cyclohexane or EtOAc/MeOH) and recycle solvents.

Comparison (general; illustrative)

  • Conventional: DMF, Pd(PPh3)4 (2–5 mol%), 80–100 °C, column chromatography.
  • Greener: 2-MeTHF or EtOH/H2O, Pd/C or modern phosphine ligands (≤1 mol%), 60–80 °C, crystallization-based isolation.

Trade-offs

  • Solubility of purines may limit use of hydrophobic solvents; co-solvent strategies or mild base adjustments can help.
  • Catalyst activity/selectivity may require optimization when changing solvent or metal.
Pharmaceutical Uses

No pharmacopeial/excipient status or formulation role is specified for this item; refer to CoA/Spec Sheet.

General, non-clinical context (literature)

  • As a functionalized purine, 8-bromoadenine is primarily a synthetic intermediate for generating 8-substituted adenine nucleosides/nucleotides that may be evaluated in discovery research.
  • In medicinal chemistry workflows, the C8–Br handle enables rapid diversification (C–C, C–N, C–O, C–S) on adenine scaffolds for SAR exploration in enzyme or receptor-binding studies.

Manufacturing/formulation considerations (research only)

  • Solid handling: high-melting, non-hygroscopic behavior is typical; facilitates weighing and storage.
  • Solution handling: DMSO or DMF concentrates can be prepared for assay addition; ensure compatibility with formulation excipients and avoid high pH where base-promoted degradation could occur over time.
  • Impurity control: Monitor for dehalogenated adenine and residual metal from cross-coupling sequences if material is used downstream in research-scale preparations.

Compliance and use restrictions

  • For research use only. Not for use in humans or diagnostic procedures. No medical claims are made for this product.
Physical Properties

Item-specific data

  • Appearance: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular Formula: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular Weight: Not specified for this item; refer to CoA/Spec Sheet.

Literature/computed (for reference; not item-specific specifications)

  • Empirical formula (literature): C5H4BrN5
  • Formula weight (literature): ~214.02 g/mol
  • Physical state: High-melting, crystalline solid; reported to decompose on strong heating (literature, typical for halogenated purines).
  • Solubility (qualitative, literature):
    • Water: low at neutral pH; improved in hot water or with pH adjustment (acidic or basic).
    • Polar aprotic solvents: soluble/sparingly soluble in DMSO and DMF; limited in acetonitrile and alcohols.
    • Aqueous buffers: better solubility in mildly basic buffers (e.g., pH 8–9) or with cosolvent (DMSO 5–20%).
  • Acid–base behavior (literature): Adenine derivatives possess multiple basic nitrogens; apparent pKa values for ring nitrogens typically in the range pKa1 ~1–2 (protonation) and pKa2 ~9–10 (exocyclic amine), but exact values depend on substitution; 8-bromo decreases basicity at C8-adjacent sites.
  • LogP/logS (qualitative): Bromination increases hydrophobicity relative to adenine; remains overall polar/heteroatom-rich.
  • UV absorbance (qualitative): Purine chromophore absorbs in the UV (≈260 nm region, literature); specific cutoff/ε not established for this item.

Note: For authoritative, lot-specific values (mp, water content, UV cutoff, metals), consult the CoA/Spec Sheet.

Quality and Grades
  • Item-specific grade/purity: Not specified for this item; refer to CoA/Spec Sheet.

How to interpret grades (general guidance)

  • Research grade: Suitable for most synthetic and biochemical research applications. Typical controls include identity (NMR/HRMS), purity (HPLC/GC/LC-MS), and appearance.
  • Assay/purity reporting: For heteroaromatic solids, HPLC area % or qNMR is commonly used. Residual solvent, water content (Karl Fischer), and inorganic residue (sulfated ash) may be included in the CoA.
  • Low-metal/trace specifications: Relevant when using Pd-catalyzed couplings on this substrate and later requiring ultralow metal residues; if critical, request trace metals data or select a grade designed for catalytic sequence use.

Stabilizers and additives

  • Stabilizer: Not typically required for purine solids; none specified for this item.
  • Impurities of note (general): Dehalogenated adenine, oxidative dimers, and inorganic halide are typical process-related impurities; chromatography or crystallization affords high purity.

What to verify for your application

  • Nucleoside synthesis: Ensure low water content and high assay purity for efficient glycosylation.
  • Cross-coupling: Confirm minimal halogen-deficient impurities; evaluate by LC-MS for dehalogenated species.
  • Bioassays and photophysics: If UV background is critical, request a UV–Vis scan or HPLC with diode-array detection.

Always defer to the lot-specific CoA/Spec Sheet for definitive specifications.

Reaction and Applications

This substrate is widely used as a functionalized purine for derivatization at the C8 position and for nucleoside assembly.

  • C8 cross-coupling (literature)

    • Suzuki–Miyaura: 8-bromoadenine couples with aryl/heteroaryl boronic acids to furnish 8-aryl adenines using Pd(0) catalysts (e.g., Pd(PPh3)4) and carbonate bases in DMF/DMAc or dioxane/H2O at 60–110 °C.
    • Sonogashira: Access 8-alkynyl adenines using Pd/Cu co-catalysis, terminal alkynes, and amine base (Et3N, DIPEA) in DMF or acetonitrile.
    • Buchwald–Hartwig-type amination: Formation of 8-arylamino derivatives with suitable ligands and bases under Pd catalysis.
  • Nucleophilic aromatic substitution (SNAr)

    • The C8–Br can be displaced by amines, thiols, or alkoxides under basic conditions (often with heat) to yield 8-amino-, 8-thio-, or 8-alkoxyadenines. Cu(I) catalysis (Ullmann-type) can accelerate C–N/O/S bond formation with aryl/heteroaryl nucleophiles.
  • N9 glycosylation to nucleosides

    • After base silylation (e.g., HMDS/TMSCl), Vorbrüggen glycosylation with activated sugars (peracetylated glycosyl donors, TMSOTf) provides 8-bromoadenosines, which are versatile intermediates for further C8 diversification on the nucleoside.
  • Research utility (non-clinical)

    • Commonly employed as a chemical probe precursor for preparing 8-substituted adenine derivatives to study nucleic acid structure, enzyme active-site recognition, or ligand–nucleobase interactions in vitro.

Practical tips

  • Dry, oxygen-free conditions improve Pd-catalyzed cross-couplings; include water only when required for base solubility.
  • Monitor for dehalogenation (adenine formation) as a side reaction; adjust catalyst/ligand and reduce temperature to suppress.
  • Protect exocyclic –NH2 when chemoselectivity is a concern (e.g., acyl or silyl protection) to direct reactivity to C8.
Reaction Conditions

The following are typical, literature-referenced conditions for 8-bromoadenine; they are general guidelines and not product specifications.

  • Suzuki–Miyaura coupling (to 8-aryl adenines)

    • Catalyst: Pd(PPh3)4 (1–3 mol%) or Pd2(dba)3/XPhos-type ligands.
    • Base: K2CO3 or Cs2CO3 (2–3 equiv).
    • Solvent: DMF, DMAc, or 1,4-dioxane/H2O (3:1 to 10:1).
    • Temperature/time: 70–100 °C, 2–16 h.
    • Notes: Protect the 6-amino group if nucleophilic side reactions occur; monitor for dehalogenation.
  • Sonogashira coupling (to 8-alkynyl adenines)

    • Catalyst/co-catalyst: PdCl2(PPh3)2 (1–2 mol%), CuI (5–10 mol%).
    • Base: Et3N or DIPEA (2–3 equiv).
    • Solvent: DMF or MeCN.
    • Temperature/time: 25–70 °C, 2–12 h.
    • Notes: Degas solvents; avoid excessive heating to limit side reactions.
  • Buchwald–Hartwig amination (to 8-arylamino derivatives)

    • Catalyst: Pd2(dba)3 (1–2 mol%) with BINAP/XantPhos; or Pd(OAc)2 with BrettPhos.
    • Base: NaOtBu or Cs2CO3.
    • Solvent: Toluene, dioxane, or CPME (with polar co-solvent if needed).
    • Temperature/time: 80–110 °C, 6–18 h.
  • SNAr with amines/thiolates

    • Base: K2CO3, NaH, or DBU (1–2 equiv).
    • Solvent: DMSO or DMF.
    • Temperature/time: 80–120 °C, 4–24 h.
    • Notes: Copper(I) salts (e.g., CuI) can accelerate coupling to O/S nucleophiles.
  • Vorbrüggen N9-glycosylation (to 8-bromoadenosines)

    • Silylation: HMDS with catalytic TMSCl or BSA, reflux to form silylated base.
    • Glycosyl donor: Peracetylated ribose with TMSOTf or SnCl4 activation.
    • Solvent: MeCN or DCM (anhydrous).
    • Temperature/time: 0–25 °C, 1–6 h (activation), then warm if necessary.

Yields vary with substrate/ligand and protection strategy; optimize on small scale before scale-up.

Safety and Handling

Authoritative safety information is provided in the product SDS. The following is general guidance for adenine derivatives and aryl bromides.

  • GHS classification and pictograms: Not specified for this item; refer to SDS.
  • Signal word / H-statements: Not specified for this item; refer to SDS.

General hazards (literature/analog-based)

  • May cause irritation to eyes, skin, and respiratory tract as a fine organic powder. Avoid dust generation and inhalation.
  • Non-volatile; thermal decomposition at elevated temperature may release HBr, nitrogenous species, and brominated organics.

Recommended PPE and engineering controls

  • Wear lab coat, safety glasses, and appropriate chemical-resistant gloves (e.g., nitrile). Handle powders in a fume hood or with local exhaust to minimize dust exposure.
  • Use antistatic measures when weighing dry powders; keep containers closed when not in use.

Incompatibilities and precautions (general)

  • Strong bases/acids can change solubility and protonation state; handle deliberately if preparing solutions.
  • Avoid strong nucleophiles or reducing agents unless intended for reaction; C8–Br is reactive under cross-coupling or SNAr conditions.
  • Moisture sensitivity: not strongly hygroscopic, but store tightly sealed to prevent caking and contamination.

First aid overview (general)

  • Inhalation: Move to fresh air; seek medical advice if symptoms persist.
  • Skin/eye contact: Rinse with water for several minutes; remove contaminated clothing; seek medical attention if irritation continues.
  • Ingestion: Rinse mouth; do not induce vomiting; obtain medical attention.

Storage and shipping (from Product Data)

  • Storage: Store at 2–8 °C.
  • Shipping: Shipped on wet ice.
Solvent Selection

Application-driven solvent choices for 8-bromoadenine (general guidance):

  • Polarity and miscibility

    • The compound is polar/heteroatom-rich but aromatic; it dissolves best in strong hydrogen-bonding or highly polar aprotic media.
    • Favor DMSO, DMF, DMAc, NMP, or formamide for stock solutions or reactions.
    • Aqueous solubility is limited at neutral pH; solubility improves in mildly basic buffers (e.g., Tris, carbonate) or with co-solvent (5–30% DMSO).
  • Selection by use case

    • Cross-coupling (Suzuki/Sonogashira): DMF, DMAc, NMP, or dioxane/H2O mixtures with base (K2CO3, Cs2CO3). Add water to aid base solvation when appropriate.
    • Nucleophilic substitutions at C8: Polar aprotic solvents (DMSO, DMF) facilitate SNAr with amines/thiolates at elevated temperature.
    • Glycosylation to nucleosides: Vorbrüggen-type conditions typically employ acetonitrile or dichloromethane with silylated base; DMF may be used for alternative protocols.
    • Biochemical assays: Prepare concentrated DMSO stocks (e.g., 10–100 mM) and dilute into buffered media; filter if needed.
  • Practical tips

    • Warm gently (40–60 °C) to effect dissolution; avoid prolonged high-temperature heating that may promote decomposition.
    • Adjust pH to 8–9 for aqueous work to enhance solubility; avoid strong base unless required by the protocol.
    • If precipitation occurs upon dilution from DMSO, increase co-solvent fraction or add surfactant-compatible buffer depending on assay constraints.
  • Alternatives to consider

    • For greener profiles, consider 2-MeTHF or cyclopentyl methyl ether for coupling workups; for dissolution, PEG-400/water or ethanol/water co-solvent systems may suffice when pH-adjusted.
Storage and Reconstitution

Item-specific storage and shipping (from Product Data)

  • Storage conditions: Store at 2–8 °C.
  • Shipped in: Wet ice.
  • Appearance: Not specified for this item; refer to CoA/Spec Sheet.

General reconstitution guidance (research use)

  • Solubility strategy: Start with anhydrous DMSO or DMF to prepare concentrated stocks (e.g., 10–100 mM). If aqueous solutions are required, dilute the organic stock slowly into buffered water with vigorous mixing.
  • pH assistance: Mildly basic buffers (pH 8–9) can improve aqueous solubility; avoid strong base unless required by the protocol.
  • Gentle warming (≤50–60 °C) and brief sonication can aid dissolution; do not overheat to prevent decomposition.

Storage of solutions

  • DMSO stocks: Store tightly capped under inert atmosphere or desiccation at 2–8 °C or freezer. Use amber vials to minimize light exposure.
  • Aqueous solutions: Prepare fresh when possible. For short-term storage (hours to a day), keep at 2–8 °C. Discard if precipitation or discoloration occurs.
  • Freeze–thaw: Minimize cycles by aliquoting. Thaw at room temperature and mix thoroughly before use.

Container and handling

  • Keep container tightly closed, protected from moisture and ambient humidity.
  • Record opening date and track solution age for reproducibility.

Always consult the lot-specific CoA/Spec Sheet and SDS for definitive handling, stability, and safety information.

Structure and Identity

Brief description: 8-Bromoadenine is a halogenated purine base derived from adenine with a bromine substituent at the C8 position of the fused imidazo[4,5-d]pyrimidine ring system.

  • Item-specific identifiers (from Product Data)

    • SKU: B353415
    • Product Name: 8-Bromoadenine
    • CAS: 6974-78-3
    • InChIKey: 93595 (as provided)
    • SMILES: Not specified for this item; refer to CoA/Spec Sheet.
  • Literature/general identifiers and composition (for reference; not item-specific)

    • Molecular formula (literature): C5H4BrN5
    • Molecular weight (literature): ~214.02 g/mol
    • Preferred IUPAC name (literature): 8-bromoadenin-9(8H)-one is not correct; common name: 8-bromoadenine (substituted adenine at C8)
    • Example SMILES (literature): Brc1ncnc2n(cnc12)N
  • Structural features (general chemistry)

    • Core scaffold: Purine (fused 6-5 bicyclic heteroaromatic).
    • Functional groups: Exocyclic primary amine at C6 (–NH2), multiple ring nitrogens (sp2), and an aryl–bromide at C8.
    • Electrophilic handle: C8–Br enables cross-coupling and substitution chemistry on the purine ring.
    • Tautomerism: Purine ring tautomers exist; N9 is typically the glycosylation site in nucleoside synthesis.
    • 2D description: A bicyclic aromatic system bearing an –NH2 on the six-membered ring and a bromine substituent at the adjacent five-membered ring carbon (C8).
Synthetic Utility

Key reactivity elements

  • Electrophilic C8–Br enables diverse bond formations on the adenine core via Pd- or Cu-catalyzed cross-coupling and via SNAr with heteroatom nucleophiles.
  • The exocyclic 6-amino group can be transiently protected (e.g., acyl, silyl, carbamate) to control chemoselectivity and regioselectivity in subsequent transformations.

Representative transformations (literature)

  • C–C coupling: Suzuki–Miyaura to install aryl/heteroaryl groups; Sonogashira to introduce alkynes; Negishi/Kumada variants for organozinc/magnesium nucleophiles (with appropriate protection and conditions).
  • C–N/O/S formation: Buchwald–Hartwig amination with anilines/alkylamines; Ullmann-type couplings to phenoxides/thiolates; direct SNAr under basic, heated conditions to give 8-amino/alkoxy/thio derivatives.
  • Directed lithiation is generally unsuitable at C8 due to the leaving group; metal–halogen exchange (e.g., with iPrMgCl·LiCl) enables further elaboration under carefully controlled, low-temperature conditions.

Nucleoside assembly

  • Vorbrüggen glycosylation of the N9 site following silylation (e.g., HMDS/TMSCl or BSA) affords 8-bromoadenosines. Subsequent C8 diversification on the nucleoside expands chemical space relevant to nucleotide chemistry.

Retrosynthetic value

  • 8-Bromoadenine functions as a convergent node: prepare the adenine core early, then diversify late at C8 to access libraries with minimal protecting-group manipulations.

Practical considerations

  • Control moisture and air in Pd-catalyzed steps; screen ligand/base/solvent to suppress dehalogenation.
  • Analyze regioisomers after nucleoside formation (N7 vs N9) and optimize silylation/activation to favor N9.
Target Specificity

Not applicable. This product is a small-molecule research chemical (a halogenated purine), not a biological targeting reagent such as an antibody or affinity probe with defined antigen specificity.

  • Item-specific target/epitope/clone/isotype data: Not specified for this item; refer to CoA/Spec Sheet if an affinity conjugate is ordered separately.

Dürfen wir Sie über Rabattaktionen informieren?

Später erinnern

Vielen Dank! Bitte überprüfen Sie Ihren E-Mail-Posteingang, um zu bestätigen.

Hoppla! Benachrichtigungen sind deaktiviert.